Analysis finds improved societal value of therapeutics for women’s cancer, highlighting health technology assessment limitations.
Broadening the perspective to include additional value elements considerably increased the overall value of treatment of women's cancer compared with the TPP, indicating that the perspective used by health technology bodies may not fully capture the societal value of therapeutics.
No takes yet. Share an insight, caveat, or question.
Brook et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: